A new Stockholm3 blood test detected 90% of prostate cancer cases, outperforming the traditional PSA test's 74% detection rate in a Swedish study. By combining protein and genetic markers with clinical risk factors, it more accurately identifies aggressive cancers while reducing unnecessary follow-up procedures, offering a promising advance in prostate cancer screening.